Chronic lymphocytic leukaemia trials in France

In France 49 Also abroad 308

49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Where
Bordeaux, Clermont-Ferrand, Créteil, Le Mans Cedex 9, Lyon, Montpellier Cedex 5, Nice, Paris, Tours Cedex 9
Age
18 years and over
People
306 worldwide
Run by
Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Marseille, Pierre-Bénite, Toulouse, Tours
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Where
Clermont-Ferrand, La Roche-sur-Yon, Lille
Age
18 years and over
People
735 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00
Phase 1Taking people
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Clermont-Ferrand, Toulouse
Age
18 years and over
People
332 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05091424
Phase 2Taking people
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Argenteuil Cedex, Caen Cedex 9, Le Mans, Mulhouse, Nice Cedex 2, Tours Cedex 9
Age
18 years and over
People
249 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Rouen
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
No phaseTaking people
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
Where
Toulouse
Age
18 years and over
People
180
Run by
Janssen Cilag S.A.S.
See details and how to joinNCT06299540
Phase 2Taking people
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Where
Nantes
Age
18 years and over
People
100 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT07221500
Phase 1/2Taking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Clermont-Ferrand, Montpellier Cedex 5, Paris, Saint-Cloud, Villejuif
Age
18 years and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Le Chesnay, Marseille, Nice, Paris, Pierre-Bénite
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
No phaseTaking people
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Where
Saint-Affrique
People
120
Run by
AstraZeneca
See details and how to joinNCT06548152
Phase 1/2Taking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
Dijon, Montpellier Cedex 5, Toulouse Cedex 9
Age
18 years and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Clermont-Ferrand, Nantes, Paris Cedex 13, Pierre-Bénite, Reims Cedex, Rennes Cedex 9, Rouen, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Angers, La Roche-sur-Yon, Nantes, Rennes, Rouen
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
No phaseTaking people
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
Where
Amiens, Nantes
Age
18 years and over
People
130
Run by
Private Hospital of Confluent, France
See details and how to joinNCT07691047
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Paris, Poitiers, Rennes
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Rouen
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 3Taking people
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Where
Angers, Clermont-Ferrand, Grenoble Cedex 9, Lille Cedex, Lyon, Marseille, Montpellier Cedex 5, Nantes, Paris, Pessac Cedex, Pierre-Bénite, Poitiers, Reims Cedex, Rennes, Rouen Cedex, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
746 worldwide
Run by
University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Brest, Nantes Cedex 2, Tours
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Pessac, Villejuif
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Bordeaux, Clermont-Ferrand, Nantes, Paris, Rouen, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Bordeaux, Clermont-Ferrand, Le Mans Cedex 9, Lille Cedex, Lyon, Montpellier Cedex 5, Toulouse Cedex 9
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
Phase 2Not yet taking people in France
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
Where
Amiens Cedex 1, Argenteuil Cedex, Avignon, Bayonne, Besançon, Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, Créteil Cedex, Epagny Metz-tessy, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lens, Libourne, Lille Cedex, Limoges, Lyon, Mulhouse, Nimes Cedex 9, ORLEANS, PARIS, Perpignan Cedex, Reims Cedex, Rouen, Saint-Brieuc, Toulouse Cedex 9, Tours, Valence, Vandoeuvre Les Nancy, Vannes
Age
18 years and over
People
42
Run by
French Innovative Leukemia Organization (F.I.L.O.).
See details and how to join2026-525763-40-00 · EU 2026-525763-40-00